Synapticure continued to build out its specialized virtual neurology platform this week, combining program expansion with internal strategic hiring. The company introduced a nationwide telehealth ataxia care program while recruiting a senior finance director to support its neurodegenerative specialty care model.
The new ataxia program targets adults with rare, clinically complex movement disorders across all 50 U.S. states. Patients gain access to virtual neurological evaluations and longitudinal care, with Synapticure able to serve as primary neurologist or co-manage cases alongside local providers.
A notable component of the initiative is at-home genetic testing integrated with pre- and post-test counseling from in-house certified genetic counselors. This precision-focused framework supports more accurate diagnosis, family risk assessment, and alignment with clinical trial education in collaboration with biopharmaceutical partners.
The program is led by Director of Movement Disorders Dr. Elizabeth Ferluga and features an education-focused partnership with Biogen, while Synapticure maintains full control over clinical operations. By addressing a patient population in the tens of thousands, the company is expanding its addressable market and diversifying revenue streams across rare and neurodegenerative conditions.
Synapticure’s medical group, CareND, remains in-network with Medicare and a growing roster of commercial insurers, supported by options for out-of-network claims and transparent self-pay pricing. This payer positioning may aid adoption as health plans seek comprehensive virtual neurology solutions compatible with emerging CMS dementia care models.
In parallel, Synapticure highlighted new research at the Alzheimer’s Association International Conference 2026, led by VP of Clinical Operations Melissa Y., M.D., FAAN. The study examines a telehealth-enabled multidisciplinary care model for neurodegenerative diseases, with a particular focus on behavioral health outcomes.
On the corporate side, Synapticure is recruiting a Finance Director to strengthen its strategic finance capabilities and long-term planning. The role will report directly to the CFO, overseeing enterprise-wide forecasting, corporate budgeting, and modeling of complex value-based care initiatives.
Responsibilities are expected to include tracking clinical trial funding streams and converting growth initiatives into structured financial plans. By targeting candidates with extensive strategic finance and digital health experience, the company aims to enhance financial discipline around scaling, reimbursement complexity, and capital allocation.
Collectively, the launch of the ataxia program, presentation of clinical research, and senior finance hiring signal Synapticure’s focus on operational growth and evidence-based care in neurodegenerative medicine. The week’s developments reinforce its positioning in precision neurology and data-driven virtual care, with improved financial oversight supporting future expansion.
Overall, Synapticure’s week reflected both clinical and organizational momentum as it deepens its nationwide reach and builds capabilities to manage evolving revenue and partnership models in specialized neurology.


